Seeger Weiss LLP Reports C.R. Bard Potentially Knew About Fatal Flaws Associated With IVC Filters

Jan 05, 2016, 21:44 ET from Seeger Weiss LLP

NEW YORK, Jan. 5, 2016 /PRNewswire/ -- Seeger Weiss LLP reports that company records obtained by NBC News show that C.R. Bard potentially knew about fatal flaws associated with the G2 series filters they manufactured. This modified version of the blood-clot filter was meant to replace the original Recovery Filter, but was similarly mired by device flaws.

The Recovery filter was found to have higher rates of relative risk of filter facture, movement, and death according to a confidential study commissioned by C.R. Bard. The G2 filter had similar problems and now, hundreds of complications and at least twelve deaths have been linked to the device.

Instead of recalling the G2 filter, C.R. Bard kept it on the market for five subsequent years. Meant to capture blood clots before they reach the heart or lungs, use of the IVC filters has been associated with certain adverse events. Confidential records show that C.R. Bard was potentially aware of reports of the G2 filter's flaws soon after it was approved by FDA. These internal documents show that executives were concerned with issues such as "caudal migration, tilting, perforation, mis-deployment."

Other adverse effects associated with IVC filters were noted in a 2010 FDA Safety Communication: "device migration, filter fracture, embolization (movement of the entire filter or fracture fragments to the heart or lungs), perforation of the IVC, and difficulty removing the device." These sorts of events may be related to how long the IVC filter was implanted and, according to a 2013 study in JAMA Internal Medicine, can cause pulmonary emboli.

Dr. William Kuo, who runs Stanford Health Care's IVC Filter Clinic, said in an NBC News investigative report that, "The number of complications, the frequency of severe failures makes it obvious that it [G2 series filter] was never safe to be implanted."

Seeger Weiss LLP is one of the nation's leading trial law firms handling complex individual, mass and class action litigation on behalf of consumers, investors, injured persons and whistleblowers. The firm, with offices in New York, Philadelphia and New Jersey, represents plaintiffs throughout litigation and as trial counsel in a variety of practice areas, including financial, securities and investment fraud, pharmaceutical injury, consumer protection, qui tam (whistleblower cases), environmental and asbestos exposures, personal injury and medical malpractice, product defect, antitrust, and commercial disputes. For more information, go to www.seegerweiss.com.

If you believe you have been injured by an IVC filter, go to http://www.seegerweiss.com/ivc-filter/lawsuit.

SOURCE Seeger Weiss LLP



RELATED LINKS

http://www.seegerweiss.com